Woodline Partners

Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.

Caris Life Sciences specializes in advanced molecular profiling technologies for cancer diagnostics and drug development. Established in 1987, it offers prognostic testing services, genomic profiling, and clinico-genomic data platforms to improve patient outcomes. The company operates globally with offices in the US and Switzerland.

Archive is a technology company that partners with leading brands like The North Face and Oscar de la Renta to create customized resale programs. These programs enable brands to take ownership of their secondhand markets, extending the life of clothing, generating new revenue streams, building customer loyalty, and driving new customer acquisition.

Tectonic Therapeutic is a biotechnology company dedicated to advancing the discovery of novel drugs targeting G Protein-Coupled Receptors (GPCRs), historically considered challenging therapeutic targets. The company's proprietary platform, GEODe, enables the development of biologic medicines aimed at modifying disease progression in areas with significant unmet medical needs.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of next-generation targeted radiotherapeutics to treat cancer patients. It is a sister company of Blue Earth Diagnostics.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for patients undergoing organ or cellular transplantation and those with autoimmune and neurodegenerative diseases. Its lead compound, tegoprubart, is an anti-CD40L antibody targeting the CD40L pathway.

Formo is Europe's first cellular agriculture company developing animal-free dairy products. It uses precision fermentation to derive real, nature-identical milk proteins, offering sustainable and ethical alternatives for consumers.

OrsoBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat severe metabolic disorders such as obesity, type 2 diabetes, lipodystrophies, and severe dyslipidemia. The company aims to restore energy homeostasis in patients by targeting pathways relevant to maintaining energy balance, thereby addressing the root causes of these conditions. OrsoBio's pipeline includes therapies intended to revolutionize the treatment of these disorders.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, dedicated to developing therapeutic antibodies for inflammation and immuno-oncology. The company employs its proprietary somatic hypermutation platform to discover and optimize antibodies that target various diseases. Among its notable product candidates are Etokimab, an anti-IL-33 treatment aimed at conditions such as atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor for generalized pustular psoriasis. AnaptysBio is also advancing a range of immuno-oncology products, including checkpoint modulators and bispecific antibodies, to address cancer treatment needs. The company collaborates with notable partners like TESARO, Celgene Corporation, and GlaxoSmithKline to enhance its research and development efforts. Founded in 2005, AnaptysBio aims to fulfill unmet medical needs through innovative antibody therapies.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Hansa Biopharma is a biopharmaceutical company focused on developing immunomodulatory treatments for individuals with rare immunological diseases. The company aims to create innovative therapies to address critical unmet medical needs in areas such as transplantation, autoimmune disorders, gene therapy, and oncology. Utilizing a proprietary antibody-cleaving enzyme technology platform, Hansa Biopharma targets pathogenic antibodies to enhance treatment outcomes. One of its key product candidates, imlifidase, is designed to facilitate kidney transplantation in sensitized patients and is also being explored for other organ and tissue transplantations, as well as acute autoimmune conditions. Operating primarily in Sweden, other European countries, and the United States, Hansa Biopharma generates the majority of its revenue from product sales.

Protara Therapeutics is a clinical-stage company focused on identifying and advancing transformative therapies for cancer and rare diseases. Its lead program, TARA-002, is an investigational cell therapy being developed for non-muscle invasive bladder cancer and lymphatic malformations, while IV choline chloride is an investigational phospholipid substrate replacement therapy for intestinal failure-associated liver disease. The company is based in New York, New York.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Mirador Therapeutics specializes in developing precision medicine technologies to tackle immune-mediated inflammatory and fibrotic diseases. The company's core offering is a proprietary data analytics engine that integrates comprehensive patient molecular profiles, pinpoints novel therapeutic targets, and facilitates the creation of targeted diagnostics. This enables researchers and healthcare providers to tailor treatments to individual patients' genetics, potentially enhancing outcomes for those with chronic conditions.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Mind Medicine Inc. is a biopharmaceutical company focused on discovering, developing, and deploying psychedelic-inspired medicines and therapies aimed at addressing addiction and mental health issues. Headquartered in New York, the company is building a diverse drug development pipeline that includes innovative treatments derived from psychedelic substances such as Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative known as 18-MC. Founded in 2010 by JR Rahn, Scott Freeman, Leonard Latchman, and Stephen L. Hurst, MindMed is actively engaged in forming collaborations and conducting clinical trials to further explore the therapeutic potential of these substances in treating brain health disorders.

Outlook Therapeutics is a late-stage biopharmaceutical company dedicated to developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently in Phase-III trials for treating wet age-related macular degeneration and other retina diseases.

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for severe autoimmune diseases through targeted therapies. The company's lead candidate, DNTH103, is a monoclonal antibody designed to selectively inhibit a specific component of the immune system, offering potential advantages over existing complement therapies. This treatment aims to improve safety and efficacy for patients suffering from serious autoimmune and inflammatory conditions. Dianthus is committed to advancing its pipeline of next-generation complement therapeutics, supported by a team of experienced professionals in the biotech and pharmaceutical sectors. The company envisions that DNTH103 could be administered as a self-injection for certain patients, enhancing convenience and accessibility in treatment.

Build A Rocket Boy Ltd is a game development company based in Edinburgh, United Kingdom, with additional studios in Budapest. Founded in 2016 and originally known as Royal Circus Limited until its name change in 2018, the company focuses on creating open-world video games that feature customizable characters and multi-narrative storylines. Its games are designed to enhance the gaming experience through cooperative multiplayer modes, allowing players to engage in immersive virtual environments. The company provides a range of services including animation, art, coding, finance, information technology, marketing, production, technical design, and analytics, all aimed at delivering innovative gaming experiences.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies aimed at transforming the treatment landscape for inflammatory bowel disease (IBD). By leveraging advanced antibody engineering, rational therapeutic combinations, and precision medicine strategies for patient selection, Spyre Therapeutics seeks to create next-generation products that address the chronic inflammation associated with IBD, which includes ulcerative colitis and Crohn's disease. The company aims to enhance existing treatment options, which currently include anti-inflammatory drugs, immunosuppressants, and biologics, thereby improving outcomes for patients suffering from these debilitating gastrointestinal disorders.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases. Its lead candidate, Diazoxide Choline Controlled Release (DCCR), an extended-release formulation of diazoxide, is being evaluated in Phase III trials for the treatment of Prader-Willi Syndrome.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Septerna is a biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). It operates a proprietary Native Complex Platform to accelerate GPCR drug discovery and aims to deliver therapies across endocrinology, immunology and inflammation, and metabolic diseases. The company is advancing a GPCR-focused pipeline with candidates such as SEP-786 (PTH1R) and SEP-631 (MRGPRX2), along with programs targeting TSHR, GLP-1R, GIPR, and GCGR, with the goal of translating GPCR biology into orally available medicines that address unmet patient needs.

Immunome is a biotechnology company specializing in immunotherapy and antigen discovery. It uses proprietary platforms to discover novel antigens and patient-derived antibodies targeting those antigens, focusing on oncology and infectious diseases.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

Founded in 2017, ElevateBio operates a portfolio of companies focused on developing, manufacturing, and commercializing transformative cell and gene therapies for severe diseases. Through strategic partnerships with leading scientists and inventors, along with a centralized facility for efficient translation of R&D into viable therapies, the company aims to deliver life-changing medicines to patients.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in developing radiopharmaceuticals as precision medicines. It focuses on creating targeted alpha therapeutics using its proprietary linker technology to enhance the safety and efficacy of these drugs, ultimately improving cancer patient outcomes.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Cedilla Therapeutics, Inc. is a biotechnology company focused on developing targeted small-molecule therapeutics for cancer and diseases linked to protein dysregulation. The company employs innovative strategies to destabilize oncoprotein targets, utilizing methods such as direct ligand-induced degradation, disruption of stabilizing protein-protein interactions, and the identification of upstream regulators that affect protein stability. Cedilla's comprehensive approach also includes large-scale proteomic analyses to map protein susceptibility, enhancing the potential for effective therapies. By concentrating on the transitions between stable and susceptible protein states, Cedilla aims to create novel treatments that broaden the applicability of small molecule therapeutics beyond oncology. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company was formerly known as Protein Stability Newco, Inc. before rebranding in 2018.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

SmartNews is a news platform that leverages machine learning algorithms to discover and deliver trending news stories across various categories, including business, technology, lifestyle, entertainment, sports, and world news. The platform evaluates tens of millions of articles and social signals to present users with the most relevant and important stories, helping them find quality information beyond traditional filter bubbles. With over 35 million downloads and more than 10 million monthly active users, SmartNews has received numerous accolades, including several "App of the Year" awards. The company has a global presence with offices in Tokyo, San Francisco, and New York, fostering an international culture that emphasizes collaboration and innovation in the quest to provide quality news to users worldwide.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.

Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Kriya Therapeutics is a gene therapy company focused on designing and developing treatments for chronic diseases. It provides an integrated platform that encompasses vector design, manufacturing, and clinical development to engineer, manufacture, characterize, and advance gene therapies. The company operates a fully integrated engine that consolidates critical infrastructure and technology to enable de novo construct design, targeted sequence modification, and data analysis, with the aim of minimizing immunogenicity and improving tissue specificity. Founded in 2019, it is based in Palo Alto, California, with an additional office in Durham, North Carolina.

Sharecare, Inc. is a digital health company that offers an online health and wellness engagement platform aimed at helping individuals manage their health comprehensively. Founded in 2009 and based in Atlanta, Georgia, Sharecare connects users to a variety of health resources and programs, allowing them to unify and navigate their health journey seamlessly. The platform features tools such as YOU, which provides visual context for understanding health conditions, and AskMD, a symptom checker offering personalized guidance. Sharecare's solutions encompass areas including chronic disease management, mental health, and preventive care, making it easier for users to engage with their health on a daily basis. By fostering a supportive environment for individuals, healthcare providers, and organizations, Sharecare promotes positive behavior change and enhances access to quality care.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Talkspace is an online therapy platform connecting users with licensed therapists, psychologists, and psychiatrists for mental health support. It offers unlimited messaging therapy, making professional help accessible and affordable.

HydraFacial is an FDA registered manufacturer of advanced aesthetic technologies and products, delivering high return on investment (ROI) opportunities. Its premier system HydraFacial® serum-based hydradermabrasion system, ranked one level above IPL for skin rejuvenation. The HydraFacial uses the patented HydroPeel® tips to resurface the skin while simultaneously infusing skin enhancing serums, including antioxidants, Hyaluronic Acid, peptide complex, and acid peels.

NeoGenomics Laboratories operates a network of cancer-focused testing facilities in the United States, Switzerland, and Singapore. The company is divided into two main segments: Clinical Services and Pharma Services. It provides a range of genetic and molecular testing services, including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing, aimed at helping clinicians and researchers understand cancer at a genetic level. Additionally, NeoGenomics offers morphologic analysis for diagnosis and supports pharmaceutical companies in their oncology programs through testing services that facilitate drug development and clinical trials. The company's collaboration with Inivata Limited for the commercialization of the InVisionFirst-Lung liquid biopsy test exemplifies its commitment to advancing cancer diagnostics. Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics serves hospitals, pathologists, oncologists, academic centers, and other clinical laboratories, enhancing cancer care through innovative testing solutions.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Patreon operates a platform that connects content creators and artists with their patrons. It enables creators to fund their work through recurring payments from patrons, who gain access to exclusive content and benefits in return.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for patients undergoing organ or cellular transplantation and those with autoimmune and neurodegenerative diseases. Its lead compound, tegoprubart, is an anti-CD40L antibody targeting the CD40L pathway.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.